Marilyn Frézier

Ms. Marilyn Frézier

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2022 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
SKSokhna Keita-Alassane
Sokhna Keita-Alassane
COColombe Otis
Colombe Otis
EBEmilie Bouet
Emilie Bouet
MGMartin Guillot
Martin Guillot
MFMarilyn Frézier
Marilyn Frézier
ETEric Troncy
Eric Troncy

24 February 2024 in Animals
Verified
Journal Article
Open access
PDF file
ADAliénor Delsart
Aliénor Delsart
COColombe Otis
Colombe Otis
VLVivian S. Y. Leung
Vivian S. Y. Leung
ÉLÉmilie Labelle
Émilie Labelle
MMMaxim Moreau
Maxim Moreau
ETEric Troncy
Eric Troncy
Veterinarians face the lack of a rapid, reliable, inexpensive, and treatment-sensitive metrological instrument reflecting feline osteoarthritis (OA) pain. The Montreal Instrument for Cat Arthritis Testing, for Use by Veterinarians (MI-CAT(V)) has been refined in 4 sub-sections, and we proposed its concurrent validation. Cats naturally affected by OA (n = 32) were randomly distributed into 4 groups of firocoxib analgesic (Gr. A: 0.40; B: 0.25; C: 0.15, and P: 0.00 mg/kg bodyweight). They were assessed during Baseline, Treatment, and Recovery periods using MI-CAT(V) and objective outcomes (effort path, stairs assay compliance, and actimetry). The MI-CAT(V) total score correlated to the effort path and actimetry (RhoS = −0.501 to −0.453; p < 0.001), also being sensitive to treatment responsiveness. The pooled treatment group improved its total, gait, and body posture scores during Treatment compared to the Baseline, Recovery, and placebo group (p < 0.05). The MI-CAT(V) suggested a dose-(especially for Gr. B) and cluster-response. Cats in the moderate and severe MI-CAT(V) clusters responded to firocoxib with a remaining analgesic effect, while the mild cluster seemed less responsive and experienced a negative rebound effect. The MI-CAT(V) was validated for its OA pain severity discriminatory abilities and sensitivity to firocoxib treatment, providing a new perspective for individualized care.

8 August 2024 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
COColombe Otis
Colombe Otis
KCKatrine-Ann Cristofanilli
Katrine-Ann Cristofanilli
MFMarilyn Frézier
Marilyn Frézier
ADAliénor Delsart
Aliénor Delsart
JMJohanne Martel-Pelletier
Johanne Martel-Pelletier
ETEric Troncy
Eric Troncy
Background: Micro-RNAs could provide great insights about the neuropathological mechanisms associated with osteoarthritis (OA) pain processing. Using the validated Montreal Induction of Rat Arthritis Testing (MI-RAT) model, this study aimed to characterize neuroepigenetic markers susceptible to correlate with innovative pain functional phenotype and targeted neuropeptide alterations.Methods: Functional biomechanical, somatosensory sensitization (peripheral–via tactile paw withdrawal threshold; central–via response to mechanical temporal summation), and diffuse noxious inhibitory control (via conditioned pain modulation) alterations were assessed sequentially in OA (n = 12) and Naïve (n = 12) rats. Joint structural, targeted spinal neuropeptides and differential expression of spinal cord micro-RNAs analyses were conducted at the sacrifice (day (D) 56).Results: The MI-RAT model caused important structural damages (reaching 35.77% of cartilage surface) compared to the Naïve group (P < 0.001). This was concomitantly associated with nociceptive sensitization: ipsilateral weight shift to the contralateral hind limb (asymmetry index) from −55.61% ± 8.50% (D7) to −26.29% ± 8.50% (D35) (P < 0.0001); mechanical pain hypersensitivity was present as soon as D7 and persisting until D56 (P < 0.008); central sensitization was evident at D21 (P = 0.038); pain endogenous inhibitory control was distinguished with higher conditioned pain modulation rate (P < 0.05) at D7, D21, and D35 as a reflect of filtrated pain perception. Somatosensory profile alterations of OA rats were translated in a persistent elevation of pro-nociceptive neuropeptides substance P and bradykinin, along with an increased expression of spinal miR-181b (P = 0.029) at D56.Conclusion: The MI-RAT OA model is associated, not only with structural lesions and static weight-bearing alterations, but also with a somatosensory profile that encompasses pain centralized sensitization, associated to active endogenous inhibitory/facilitatory controls, and corresponding neuropeptidomic and neuroepigenetic alterations. This preliminary neuroepigenetic research confirms the crucial role of pain endogenous inhibitory control in the development of OA chronic pain (not only hypersensitivity) and validates the MI-RAT model for its study.

Verified
Journal Article
Open access
PDF file
COColombe Otis
Colombe Otis
EBEmilie Bouet
Emilie Bouet
SKSokhna Keita-Alassane
Sokhna Keita-Alassane
MFMarilyn Frézier
Marilyn Frézier
ADAliénor Delsart
Aliénor Delsart
ETEric Troncy
Eric Troncy
Validating animal pain models is crucial to enhancing translational research and response to pharmacological treatment. This study investigated the effects of a calibrated slight exercise protocol alone or combined with multimodal analgesia on sensory sensitivity, neuroproteomics, and joint structural components in the MI-RAT model. Joint instability was induced surgically on day (D) 0 in female rats (N = 48) distributed into sedentary–placebo, exercise–placebo, sedentary–positive analgesic (PA), and exercise–PA groups. Daily analgesic treatment (D3–D56) included pregabalin and carprofen. Quantitative sensory testing was achieved temporally (D–1, D7, D21, D56), while cartilage alteration (modified Mankin’s score (mMs)) and targeted spinal pain neuropeptide were quantified upon sacrifice. Compared with the sedentary–placebo (presenting allodynia from D7), the exercise–placebo group showed an increase in sensitivity threshold (p < 0.04 on D7, D21, and D56). PA treatment was efficient on D56 (p = 0.001) and presented a synergic anti-allodynic effect with exercise from D21 to D56 (p < 0.0001). Histological assessment demonstrated a detrimental influence of exercise (mMs = 33.3%) compared with sedentary counterparts (mMs = 12.0%; p < 0.001), with more mature transformations. Spinal neuropeptide concentration was correlated with sensory sensitization and modulation sites (inflammation and endogenous inhibitory control) of the forced mobility effect. The surgical MI-RAT OA model coupled with calibrated slight exercise demonstrated face and predictive validity, an assurance of higher clinical translatability.

Verified
Journal Article
Open access
PDF file
ADAliénor Delsart
Aliénor Delsart
MMMaxim Moreau
Maxim Moreau
COColombe Otis
Colombe Otis
MFMarilyn Frézier
Marilyn Frézier
MDMarlene Drag
Marlene Drag
ETEric Troncy
Eric Troncy
The metrological properties of two performance-based outcome measures of feline osteoarthritis (OA), namely Effort Path (Path) and Stairs Assay Compliance (Stairs), were tested. Cats naturally affected by OA (n = 32) were randomly distributed into four groups (A: 0.40, B: 0.25, C: 0.15, or D: 0.00 mg firocoxib/kg bodyweight) and assessed during baseline, treatment, and recovery periods. For Path, from an elevated walking platform, the cats landed on a pressure-sensitive mattress and jumped up onto a second elevated platform. Analysis included velocity, time to completion, peak vertical force (PVF), and vertical impulse. For Stairs, the number of steps and time to completion were recorded for 16 steps up and down in a 4 min period. Reliability was moderate to very good for Path and poor to good for Stairs. Different normalization methods are described in the manuscript. The placebo group remained stable within-time in Path, whereas treated cats trotted faster on the ramp (p < 0.0001), improved their PVF (p < 0.018) and completed the task quicker (p = 0.003). The percentage of cats completing the Stairs finish line was higher under treatment (p < 0.036), with huge effect size, the placebo group results being stable within-time. Both are promising performance-based outcome measures to better diagnose and manage feline OA pain.

Verified
Journal Article
Open access
PDF file
MFMarilyn Frézier
Marilyn Frézier
COColombe Otis
Colombe Otis
ELEmilie Labelle
Emilie Labelle
BLBertrand Lussier
Bertrand Lussier
PGPierrette GAUDREAU
Pierrette GAUDREAU
ETEric Troncy
Eric Troncy
To investigate the involvement of gut–brain axis in musculoskeletal chronic pain in the elderly, this preclinical study aimed to compare osteoarthritis (OA) pain expression, cognitive function and gut microbiota composition in two aging rat strains (11–15 months). A validated surgically induced OA model was used in Sprague-Dawley (SD; n = 12), as standard group, and in LOU/C/Jall rats (LOU; n = 8), a healthy aging model. The OA pain response was assessed longitudinally (60 days) through quantitative sensory testing (mechanical sensitization and endogenous inhibitory control functionality), spatial memory, and gut microbiota. At sacrifice, joint structural alterations and spinal neuropeptides concentrations were quantified. After OA induction, higher mechanical hypersensitivity in LOU than in SD was also associated with higher endogenous inhibitory control (p < 0.05). Expression of pro-/anti-nociceptive spinal neuropeptides, cognitive function and joint alterations were similar in both groups. Gut microbiota composition was different (p < 0.001) and different taxa were associated with each strain (e.g., Akkermansia spp. with LOU vs. Lactobacillus spp. with SD). This study suggests healthy aging to be associated with more efficient endogenous pain control and expression of specific intestinal bacteria. This research questions the implication of the intestinal microbiota in aging and chronic pain control.